Loading quotes...
Forecast
The analysts' average price target is €168.07 (-5.15%). The median is €169.56 (-4.31%).
| Buy |
16 |
| Hold |
17 |
| Sell |
1 |
News Go to news feed
Fairview introduces BD Vmax 160 pharmacy robot in the US
Fairview Health Services has become the first US health system to put the BD Vmax 160 pharmacy automation robot into operation. The system automates storage, tracking and picking, particularly for specialty therapies and temperature-controlled medications, and is designed for temperatures of 2–8 °C. The BD Vmax 160 offers automatic replenishment with BD EasyLoad (three seconds loading time per container, 99.8% accuracy), automated labeling for all 50 US states and expiration-date recognition to prevent dispensing expired products. The implementation complements BD’s existing pharmacy automation solutions and the Incada Connected Care Platform. » More on de.investing.com
Becton Dickinson climbs to 52-week high after strong Q3 results
Becton Dickinson’s stock reached $187.50, marking a 52-week high after gaining 19.65% year-to-date. In the third fiscal quarter the company beat analysts’ expectations with adjusted earnings of $3.23 per share and revenue of $5.0 billion. Becton Dickinson subsequently raised its full-year guidance; InvestingPro also notes the dividend has been increased every year for 55 years. » More on de.investing.com
BD appoints Gary Sorsher as executive vice president and chief quality officer
BD appoints Gary Sorsher, effective September 8, as executive vice president and chief quality officer. Sorsher has more than 30 years of experience in senior quality roles and was most recently chief quality officer at Edwards Lifesciences. At the same time, Jeffrey Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years with the company (joined 1998). BD emphasizes the importance of quality for customer and patient trust; the company operates globally in medical technology, biopharma systems and interventional therapies. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 4.37B | 6.59% |
| Gross profit | 2.03B | 9.23% |
| Net profit | 330.33M | 32.17% |
| EBITDA | 1.09B | 9.80% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €47.44B |
Number of shares | 272.39M |
52-week high/low | €178.90 - €113.86 |
Dividend yield | 2.06% |
Dividends TTM | €3.65 |
Beta | 0.28 |
P/E ratio | 58.78 |
PEG ratio | -1.46 |
P/B ratio | 2.20 |
P/S ratio | 2.55 |
Company profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
| Name | Becton Dickinson |
| CEO | Thomas E. Polen Jr. |
| Headquarters | Franklin Lakes,
nj USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Technology |
| IPO | 02/21/1973 |
| Employees | 72,000 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | BDX |
London Stock Exchange | 0R19.L |
XETRA | BOX.DE |
Frankfurt | BOX.F |
Düsseldorf | BOX.DU |
Milan | 1BDX.MI |
London | 0R19.L |
SIX | BDX.SW |
München | BOX.MU |
Wien | BDX.VI |